- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT07943949
Effect of a Comprehensive Package Based on Multimarker Blood-based Point-of-care Testing on Antibiotic Prescribing for Acute Respiratory Tract Infections at Village Clinics in China
This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China.
Tutkimuksen yleiskatsaus
Tila
Interventio / Hoito
Yksityiskohtainen kuvaus
This is a pragmatic, parallel-group, superiority, cluster-randomised controlled trial designed to evaluate the effect of a comprehensive intervention package, based on multimarker blood-based POCT on antibiotic prescribing for ARIs in village clinics in China. We will conduct the trial over six months in 80 village clinics across 10 townships in Xiantao and Jingmen, Hubei Province (with 5 townships in Xiantao and 5 in Jingmen). Village clinics will be randomly assigned in a 1:1 ratio to either the intervention or control group, stratified by city and township. A comprehensive intervention package based on multimarker blood-based POCT will be implemented in 40 village clinics within the intervention group. In addition to equipping these clinics with POCT devices, we will provide systematic guidance through a combination of centralised training sessions and the distribution of training manuals. The training will focus on the standardised operation of POCT and clinical pathways to guide antibiotic prescriptions for the treatment of ARIs based on test results. We will provide patient education through leaflets, primarily aimed at helping rural patients understand how multimarker blood-based POCT can aid in their diagnosis and treatment, thereby improving patient acceptance. The control group will undergo diagnosis and treatment in accordance with routine care procedures, without any intervention.
Opintotyyppi
Ilmoittautuminen (Arvioitu)
Vaihe
- Ei sovellettavissa
Yhteystiedot ja paikat
Opiskeluyhteys
- Nimi: Xiaoxv Yin
- Puhelinnumero: +86 13871187781
- Sähköposti: yxx@hust.edu.cn
Tutki yhteystietojen varmuuskopiointi
- Nimi: Minzhi Xu
- Puhelinnumero: +86 18737357795
- Sähköposti: 619581384@qq.com
Opiskelupaikat
-
-
Hubei
-
Jingmen, Hubei, Kiina, 448000
- 40 Village Clinics
-
Ottaa yhteyttä:
- Minzhi Xu
- Puhelinnumero: +86 18737357795
- Sähköposti: 619581384@qq.com
-
Ottaa yhteyttä:
- Yifei Chen
- Puhelinnumero: +86 18186446642
- Sähköposti: 2026521006@hust.edu.cn
-
Xiantao, Hubei, Kiina, 433000
- 40 Village Clinics
-
Ottaa yhteyttä:
- Minzhi Xu
- Puhelinnumero: +86 18737357795
- Sähköposti: 619581384@qq.com
-
Ottaa yhteyttä:
- Yifei Chen
- Puhelinnumero: +86 18186446642
- Sähköposti: 2026521006@hust.edu.cn
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
- Lapsi
- Aikuinen
- Vanhempi Aikuinen
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Eligibility criteria for clusters. Village clinics will be eligible if they have not previously participated in a POCT-guided antibiotic prescribing programme, record more than 2,000 outpatient visits annually, manage an average of at least 10 patients with ARIs per week, and have licensed prescribers. Eligibility will be verified using prescription records from the preceding year obtained from the information management departments of the local health authorities.
Eligibility criteria for participants. The target population comprises patients of all ages who either (1) have been diagnosed by village doctors with an ARI, including upper or lower respiratory tract infections; or (2) present with at least one acute respiratory symptom or sign, such as cough, sore throat, rhinitis (nasal congestion, sneezing, or rhinorrhoea), wheezing, or abnormal findings on auscultation. Patients diagnosed with non-respiratory conditions and those whom village doctors consider require referral to a higher-level healthcare facility based on their clinical presentation will be excluded.
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Hoito
- Jako: Satunnaistettu
- Inventiomalli: Rinnakkaistehtävä
- Naamiointi: Yksittäinen
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
|---|---|
|
Ei väliintuloa: Control group
The control group will not have any intervention, as the control (usual care) |
|
|
Kokeellinen: Intervention group
All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs. |
All village clinics in the intervention group will be provided with a combined POCT system for CBC parameters, CRP, and SAA, together with the required reagent kits, for use in patients with ARIs. Each intervention clinic will receive a concise, easy-to-follow decision flowchart summarising the prespecified thresholds for selected CBC parameters, CRP, and SAA. Following randomisation, all village doctors in the intervention group will receive standardised centralised training. The research team will also provide each village clinic in the intervention group with a guidance manual on appropriate antibiotic use for ARIs supported by combined CBC, CRP, and SAA POCT. Plain-language, non-technical information leaflets will be distributed at all village clinics in the intervention group. |
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
|---|---|---|
|
The primary outcome will be a binary indicator of whether at least one antibiotic is prescribed by the village doctor during an eligible index consultation for an ARI.
Aikaikkuna: The 6-month intervention
|
An index consultation is defined as an ARI-related consultation by a patient who has not had any recorded ARI consultations at the same village clinic in the preceding 14 days. This measure aims to capture the overall effect of the POCT-supported multicomponent intervention on antibiotic prescribing decisions for ARIs. Since most ARIs are viral and self-limiting, a lower prescribing proportion-provided that patient recovery and safety are not compromised-would indicate more selective use of antibiotics by village doctors. This endpoint is particularly suitable for research in village clinics in China because prescriptions are now routinely recorded electronically rather than solely on paper. These digital records enable standardised data extraction and auditing, thereby supporting the completeness and traceability of outcome ascertainment. |
The 6-month intervention
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
The proportion of eligible index consultations in which two or more antibiotics are prescribed
Aikaikkuna: The 6-month intervention
|
The 6-month intervention
|
|
The proportion in which at least one antibiotic is administered intravenously
Aikaikkuna: The 6-month intervention
|
The 6-month intervention
|
|
The proportion in which at least one traditional Chinese medicine is prescribed
Aikaikkuna: The 6-month intervention
|
The 6-month intervention
|
|
The medication cost per eligible index consultation
Aikaikkuna: The 6-month intervention
|
The 6-month intervention
|
|
The total cost per eligible index consultation
Aikaikkuna: The 6-month intervention
|
The 6-month intervention
|
Muut tulostoimenpiteet
Tulosmittaus |
Aikaikkuna |
|---|---|
|
The proportion of patients who initiate any additional antibiotic during the 14 days following an eligible index consultation for an ARI will be assessed in a randomly selected subsample
Aikaikkuna: The 6-month intervention
|
The 6-month intervention
|
|
The principal safety outcome will be the proportion of patients admitted to any hospital within the corresponding study city for an ARI or sepsis within 30 days after the index consultation.
Aikaikkuna: The 6-month intervention
|
The 6-month intervention
|
|
In the randomly selected patient subsample, we will also assess time to recovery from ARI symptoms through the 14-day telephone follow-up.
Aikaikkuna: From the index consultation to the end of treatment at 2 weeks
|
From the index consultation to the end of treatment at 2 weeks
|
Yhteistyökumppanit ja tutkijat
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Arvioitu)
Ensisijainen valmistuminen (Arvioitu)
Opintojen valmistuminen (Arvioitu)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Muut tutkimustunnusnumerot
- HuazhongU20261111
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .